Blaze Bioscience, a Seattle biotechnology company, said it has completed an $8.5 million financing and will use the money for early clinical trials of a product for visualizing cancer tumors during surgery.

The company’s Tumor Paint technology attaches a fluorescing “beacon” to a molecule that targets solid tumors; the goal is to highlight cancer cells so they can be completely removed.

Blaze, a spin-off using discoveries at the Fred Hutchinson Cancer Research Center, has now attracted $9.8 million since its founding in 2010.